elder law weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of elder law weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Carrington Laboratories, Inc.
Positive progress reported on powder vaccine delivery technology
June 23rd, 2004
Carrington Laboratories, Inc., (CARN) announced that preclinical studies of its DelSite subsidiary's GelVac intranasal powder vaccine delivery system demonstrated that GelVac formulations persist for an extended period of time in the nasal cavity, conferring sustained antigen release and significantly increasing serum IgG and lung IgA responses against inactivated influenza antigen in animal models. The results were presented Wednesday at the 1st International Conference on Influenza Vaccines for the World in Lisbon, Portugal by Yawei Ni, PhD, group leader for discovery, research and vaccine development, of Carrington's DelSite Biotechnologies subsidiary. ...
Source: elder law weekly (2004-06-23)
|
